Cooper Financial Group Buys 564 Shares of Eli Lilly and Company $LLY

Cooper Financial Group grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 12.0% in the second quarter, HoldingsChannel.com reports. The fund owned 5,274 shares of the company’s stock after acquiring an additional 564 shares during the quarter. Cooper Financial Group’s holdings in Eli Lilly and Company were worth $6,325,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Willner & Heller LLC boosted its holdings in shares of Eli Lilly and Company by 1.0% in the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after purchasing an additional 9 shares in the last quarter. Tanager Wealth Management LLP increased its stake in shares of Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after buying an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC boosted its position in Eli Lilly and Company by 1.5% during the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after buying an additional 10 shares during the period. Wealthspan Partners LLC grew its holdings in Eli Lilly and Company by 0.5% during the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after acquiring an additional 10 shares during the last quarter. Finally, G&S Capital LLC increased its position in Eli Lilly and Company by 2.0% in the 4th quarter. G&S Capital LLC now owns 501 shares of the company’s stock valued at $538,000 after acquiring an additional 10 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported second-quarter revenue of approximately $22.97 billion, up 47.7% year over year and well above analysts’ expectations near $20.7 billion. Adjusted EPS of $8.38 substantially exceeded the consensus estimate of $6.16. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: Mounjaro sales reportedly surged 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly sales. The performance indicates that demand for Lilly’s diabetes and weight-loss treatments remains strong and is driving the company’s earnings growth. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $85 billion-$87 billion from $82 billion-$85 billion. Management also highlighted accelerating adoption of Foundayo, broader Medicare obesity-drug access and progress toward a potential 2027 retatrutide filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analyst optimism remains elevated: Cantor Fitzgerald raised its price target to $1,410 and maintained an “overweight” rating. Coverage also emphasizes that Lilly is widening its lead over Novo Nordisk, whose recent results have raised concerns about competitive momentum. The divide between Eli Lilly and Novo Nordisk is widening
• Neutral Sentiment: Amazon’s planned $50-per-month Medicare access to Wegovy, Zepbound and Foundayo could expand distribution and patient access, but greater retail availability may also increase price competition and payer pressure.
• Negative Sentiment: Several analysts caution that Lilly’s valuation and heavy reliance on GLP-1 products leave the shares vulnerable if demand, manufacturing capacity or competitive conditions weaken.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on LLY. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a report on Thursday. Bank of America raised their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Rothschild & Co Redburn lifted their target price on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Berenberg Bank upped their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research report on Monday, June 22nd. Finally, Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,293.71.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,191.87 on Friday. The firm has a market cap of $1.12 trillion, a PE ratio of 40.00, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a 50-day moving average price of $1,157.76 and a 200-day moving average price of $1,046.57. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 103.84% and a net margin of 33.53%.The firm’s revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 36 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.